Endo chief meets healthcare reform head-on

Anticipating the effects of U.S. healthcare reform, Endo Pharmaceuticals Chief Executive David Holveck says his company is diversifying beyond pain medications into other maladies--and beyond drugs, into diagnostics, devices and health services. Report